Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
Holding BDRX?
Track your performance easily
BDRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.50 - $220.25
Previous Close$3.85
Volume4.79M
Average Volume (3M)163.71K
Market Cap
$2.72M
Enterprise Value-$5.16M
Total Cash (Recent Filing)£6.42M
Total Debt (Recent Filing)£713.00K
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Apr 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-49.74
Shares Outstanding580,840
10 Day Avg. Volume35,619
30 Day Avg. Volume163,705
Standard Deviation0.26
R-Squared0.08
Alpha-0.13
Financial Highlights & Ratios
Price to Book (P/B)0.30
Price to Sales (P/S)3.33
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Biodexa Pharmaceuticals News
PremiumCompany Announcements
Biodexa Pharmaceuticals Secures Nasdaq Listing Compliance
PremiumCompany Announcements
Biodexa Pharmaceuticals Plans Strategic Share Value Adjustment
PremiumCompany Announcements
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod
PremiumCompany Announcements
Biodexa Pharmaceuticals Secures Nasdaq Compliance ExtensionOwnership Overview
11.77%
Insiders
― Other Institutional Investors
88.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $3.50 and its highest was $220.25 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Currently, no data Available
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Apr 25, 2025 which is in 155 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Sep 26, 2024. The company reported -$0.033 earnings per share for the quarter, missing the consensus estimate of -$0.022 by -$0.011.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 580,840 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of -$0.033 in its last earnings report, missing expectations of -$0.022. Following the earnings report the stock price went up 1.097%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
---
Biodexa Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
BDRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.27%
12-Months-Change
Fundamentals
Return on Equity
-96.61%
Trailing 12-Months
Asset Growth
74.43%
Trailing 12-Months
Company Description
Biodexa Pharmaceuticals
Midatech Pharma PLC is a part of the healthcare sector. As a pharmaceutical company, it focuses on commercializing and developing products in oncology and other therapeutic areas. The company has only one operating segment Pipeline Research and Development. The research and development activities involve the discovery and development of pharmaceutical products in the field of nanomedicine and sustained release technology.
---
BDRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aileron Therapeutics
―
Anixa Biosciences
―
Actinium Pharmaceuticals
―
Crispr Therapeutics AG
―
Best Analysts Covering BDRX
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-88.10%
initiated a buy rating 10 months ago
Copying Aydin Huseynov's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -88.10% per trade.
---